2019
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
Copel JA, Platt LD, Hobbins JC, Afshar Y, Grechukhina O, Mallampati D, Bromley B, Caughey AB, Grobman W, Han CS, Nicolaides K, Pettker C, Saade G, Sibai B, Simhan H, Sonek J, Werner E, Chescheir N. Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstetrics And Gynecology 2019, 135: 36-45. PMID: 31809427, DOI: 10.1097/aog.0000000000003582.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEarly-onset preeclampsiaSubstantial economic burdenCost-effectiveness dataAspirin prophylaxisNeonatal morbidityPreterm preeclampsiaProphylactic usePreventive strategiesEconomic burdenPreeclampsiaCurrent professional guidelinesRisk assessment strategiesRisk assessmentPractice changeDifferent assessment toolsSpecific knowledge gapsAspirinUnited StatesTarget populationConsequent interventionsFeasibility of implementationProfessional guidelinesAssessment toolAvailable literatureRisk
2017
First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume
Sonek J, Krantz D, Carmichael J, Downing C, Jessup K, Haidar Z, Ho S, Hallahan T, Kliman HJ, McKenna D. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume. American Journal Of Obstetrics And Gynecology 2017, 218: 126.e1-126.e13. PMID: 29097177, DOI: 10.1016/j.ajog.2017.10.024.Peer-Reviewed Original ResearchConceptsLate-onset preeclampsiaEarly-onset preeclampsiaFirst-trimester screeningWeeks' gestationMaternal characteristicsPlacental volumeUterine artery pulsatility indexArtery pulsatility indexRisk of preeclampsiaAddition of biomarkersDiagnosis of preeclampsiaDetection rateFalse positive rateMaternal biomarkersCombination of markersLate preeclampsiaPerinatal morbidityCohort studyOnset preeclampsiaArterial pressurePulsatility indexFirst trimesterMedical historySerum biomarkersMedical records
2015
Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply